Ex-vivo treatment of T-cells with IFN-λ
AssigneeMedical Diagnostics Laboratories, LLC
InventorsGrant Gallagher, Joyce Gallagher, Sshekar Srinivas, Jihong Dai, Nicholas Megjugorac, Grant E. Gallagher
Life of this patent
Estimating the term…
Abstract
The present invention provides a method of treating Th2-associated diseases and disorders by modulating the expression or secretion of IL-4, IL-5 and IL-13 using interferon lambda (IFN-λ). For Th2-associated diseases and disorders, cells of a patient having a Th2-associated disease or disorder are treated ex vivo, with IFN-λ and returned to the patient. The present invention also provides a method of ex vivo treatment, in conjunction with co-administration of IFN-λ.
Claims15
A method of ex vivo treatment of T-cells, comprising the steps:
- (a) obtaining peripheral blood from a human subject suffering from asthma;
- (b) isolating mononuclear cells from said peripheral blood;
- (c) purifying T-cells from said isolated mononuclear cells;
- (d) exposing said purified T-cells to IFN-λ;
- and
- (e) administering said exposed cells to said human subject,
- wherein said IFN-λ is present in an amount sufficient to inhibit stimulus-induced cytokine release, and
- wherein said stimulus is selected from the group consisting of Concanavalin A and anti-CD2/3/28 beads and said cytokine is at least one compound selected from the group consisting of IL-4 and IL-5.
Dependencies are inferred from the claim text.